Sep 28

QP 22 - Refining Prostate Cancer Care: Integration, Innovation, and Outcomes

1127 - Duration of Androgen Receptor Pathway Inhibitor and ADT with Metastasis Directed Therapy In Oligometastatic Cancer of the Prostate (DIRECT): A Phase 2 Randomized Trial

05:05pm - 05:10pm ET

Presenter(s)

Rachel Glicksman, MD - University of Toronto, Toronto, ON